Mini Review
A decade of targeted therapy for non-small cell lung cancer
Khalid Abu Ajaj*
Published: 28 September, 2017 | Volume 1 - Issue 1 | Pages: 023-027
Chemotherapy is one of the main treatment options for cancer. However, chemotherapeutic agents usually suffer from poor pharmaceutical properties that restrict their use. Targeted therapy drugs have been developed to specifically target changes in cancer cells that help these cells to grow. Such drugs often work when standard chemotherapeutic drugs do not, they often have less severe side effects and they are most often used for advanced cancers. The objective of this article is to give an overview about the 16 FDA-approved targeted therapy drugs to treat non-small cell lung cancer.
Read Full Article HTML
DOI: 10.29328/journal.jprr.1001005
Cite this Article
Read Full Article PDF
References
- Dolly SO, Collins DC, Sundar R, Popat S, Yap TA. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs. 2017; 77: 813-827. Ref.: https://goo.gl/XjqRJw
- No Authors. FDA approves Avastin in combination with chemotherapy for first-line treatment of most common type of lung cancer. Cancer Biol Ther. 2006; 5: 1425-1428. Ref.: https://goo.gl/wRvL5W
- Markham A. Brigatinib: First Global Approval. Drugs. 2017; 77: 1131-1135. Ref.: https://goo.gl/bEYp8G
- fda.gov.
- Horn L, Sandler A. Chemotherapy and antiangiogenic agents in non-small-cell lung cancer. Clin Lung Cancer. 2007; 8: 68-73. Ref.: https://goo.gl/bbKEXJ
- Hennequin C. Targeted therapies and radiotherapy in lung cancer. Cancer Radiother. 2007; 11: 77-83. Ref.: https://goo.gl/KFgHJm
- Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015; 23: 32-38. Ref.: https://goo.gl/fr4u92
- Cardones AR, Banez LL. VEGF inhibitors in cancer therapy. Curr Pharm Des. 2006; 12: 387-394. Ref.: https://goo.gl/auKpiw
- Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006; 28: 1779-1802. Ref.: https://goo.gl/dgq4Ud
- Aprile G, Rijavec E, Fontanella C, Rihawi K, Grossi F. Ramucirumab: preclinical research and clinical development. Onco Targets Ther. 2014; 7: 1997-2006. Ref.: https://goo.gl/VGbGe5
- Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015; 8; 49-53. Ref.: https://goo.gl/m7YmSt
- Metro G, Finocchiaro G, Toschi L, Elisabetta M, Alessandra C, et al. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials. 2006; 1: 1-13. Ref.: https://goo.gl/x25PLq
- Pillai RN, Ramalingam SS. Necitumumab: a new therapeutic option for squamous cell lung cancer? Transl Lung Cancer Res. 2014; 3: 382-383. Ref.: https://goo.gl/nCpDgg
- Fala L. Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2016; 9; 119-122. Ref.: https://goo.gl/gGFrbV
- McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc). 2015; 51: 7-20. Ref.: https://goo.gl/eJCaXN
- Lim SH, Sun JM, Lee SH, Ahn JS, Park K, et al. Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin Biol Ther. 2016; 16: 397-406. Ref.: https://goo.gl/TPPqxn
- Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, He K, et al. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist. 2017. Ref.: https://goo.gl/56EANN
- Krishnamurthy A, Jimeno A. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers. Drugs Today (Barc). 2017; 53: 217-237. Ref.: https://goo.gl/vfSHk4
- Markham A. Atezolizumab: First Global Approval. Drugs. 2016; 76: 1227-1232. Ref.: https://goo.gl/uUc3un
- Flippot R, Fallet V, Besse B, Wislez M, Vignot S, et al. Nivolumab, a new hope in non-small cell lung cancer. Bull Cancer. 2015; 102: 1046-1052. Ref.: https://goo.gl/UnmCy2
- Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, et al. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer with Progression on or After Platinum-Based Chemotherapy. Oncologist. 2016; 21: 634-642. Ref.: https://goo.gl/ErnYGR
- Takahama T, Sakai K, Takeda M, Azuma K, Hida T, et al. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Oncotarget. 2016; 7: 58492-58499. Ref.: https://goo.gl/qdMcK5
- Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, et al. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud. 2017; 3: 001115. Ref.: https://goo.gl/w8W2wP
- Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015; 10: 1396-403. Ref.: https://goo.gl/2SJBL4
- Takeda M, Nakagawa K. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer. Curr Cancer Drug Targets. 2015; 15: 792-802. Ref.: https://goo.gl/tCiSYs
- Ostoros G, Dome B. [Erlotinib in the treatment of non-small cell lung cancer]. Magy Onkol. 2006; 50: 237-241. Ref.: https://goo.gl/vdVRUy
- Cohen MH, Johnson JR, Chattopadhyay S, Tang S, Justice R, et al. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist. 2010; 15: 1344-1351. Ref.: https://goo.gl/Ue64Uj
- Khozin S, Gideon M. Blumenthal, Xiaoping Jiang, Kun He, Karen Boyd, et al. U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Oncologist. 2014; 19: 774-779. Ref.: https://goo.gl/gRPh6T
- Nelson V, Ziehr J, Agulnik M, Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther. 2013; 6: 135-143. Ref.: https://goo.gl/Z5X565
- Dungo RT, Keating GM. Afatinib: first global approval. Drugs. 2013; 73: 1503-1515. Ref.: https://goo.gl/5iW5ny
- Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2010; 11: 1343-1357. Ref.: https://goo.gl/JDPmM8
- No author listed. Gefitinib Approved for EGFR-Mutated NSCLC. Cancer Discov. 2015; 5: 896. Ref.: https://goo.gl/MrygSG
- McCoach CE, Jimeno A. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations. Drugs Today (Barc). 2016; 52: 561-568. Ref.: https://goo.gl/oUoXud
- Greig SL. Osimertinib: First Global Approval. Drugs. 2016; 76: 263-273. Ref.: https://goo.gl/naWk1f
- Ou SH. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. Expert Rev Anticancer Ther. 2012; 12: 151-162. Ref.: https://goo.gl/ojZoKx
- Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw. 2011; 9: 1335-1341. Ref.: https://goo.gl/qPGzc7
- Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 2016; 469: 489-503. Ref.: https://goo.gl/uRyTWQ
- Cooper MR, Chim H, Chan H, Durand C. Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer. Ann Pharmacother. 2015; 49: 107-112. Ref.: https://goo.gl/xYRmGt
- Guha M. Novartis' lung cancer ALK inhibitor approved. Nat Biotechnol, 2014; 32: 607. Ref.: https://goo.gl/aP2c6g
- Avrillon V, Perol M. Alectinib for treatment of ALK-positive non-small-cell lung cancer. Future Oncol. 2017; 13: 321-335. Ref.: https://goo.gl/6A5Gfp
- Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, et al. FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib. Clin Cancer Res. 2016; 22: 5171-5176. Ref.: https://goo.gl/2KALyE
- Siaw JT, Wan H, Pfeifer K, Rivera VM, Guan J, et al. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Oncotarget. 2016; 7: 29011-29022. Ref.: https://goo.gl/d1cbXg
- Asati V, Bharti SK, Mahapatra DK. Mutant B-Raf Kinase Inhibitors as Anticancer Agents. Anticancer Agents Med Chem. 2016; 16: 1558-1575. Ref.: https://goo.gl/VdGM8T
- Smida M, Fece de la Cruz F, Kerzendorfer C, Uras IZ, Mair B, et al. MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated. Nat Commun. 2016; 7: 13701. Ref.: https://goo.gl/oGb69r